Citations

Clear

4847 citation(s) found for "Yu, Eric".

P3797Increased risk of cardiovascular events and stroke among patients with atrial fibrillation and obstructive sleep apnea
Dalgaard, Frederik , North, Rebecca, Pieper, Karen S. , Kowey, Peter R. , Piccini, Jonathan P. , Steinberg, Benjamin A. , Mahaffey, Kenneth W. , Fonarow, Gregg C. , Gersh, Bernard J. , Pokorney, Sean D. , Peterson, Eric D.

Mayo Clinic

European Heart Journal | October 21, 2019 | Volume: 40 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehz745.0642 Get It

Abstract Background Obstructive sleep apnea (OSA) is common in patients with atrial fibrillation (AF). It is not well understood if OSA impacts cardiovascular outcomes in patients with AF. Purpose To investigate patient characteristics and major adverse cardiovascular and neurological events (MACNE) in patients with AF and OSA. Methods Using the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) and ORBIT-AF II we compared the adjusted risk of the composite of cardiovascular death, myocardial infarction, stroke/transient ischemic attack/non-CNS embolism (stroke/SE), and new-onset heart failure (MACNE) according to the presence or absence of OSA, using multivariable adjusted Cox proportional hazard models. Secondary outcomes were the individual components of MACNE. Results Among 22,760 patients with AF, there were 4,045 (17.8%) with OSA at baseline. Median follow-up time was 1.5 (IQR: 1–2.2) years. OSA patients were younger (median [IQR] 68 [61–75] years vs. 74 [66–81] years, were more likely to be male (70.7% vs. 55.3%), and had markedly increased body mass index (BMI) (median 34.6 kg/m2 [29.8–40.2] vs. 28.7 kg/m2 [25.2–33.0]). Those with OSA had a higher prevalence of diabetes (39.2% vs. 25.2%), chronic obstructive pulmonary disease (COPD) (20% vs. 12%), heart failure (32.2% vs. 25.1%), and hyperlipidemia (73.2% vs. 66.7%). After adjustment, the presence of OSA was significantly associated with MACNE (HR: 1.16 [95% CI: 1.03–1.31], p=0.011) [Figure]. Stroke/SE was higher in patients with OSA (HR: 1.38 [95% CI 1.12–1.70], p=0.003). Addition of OSA to a model containing the CHA2DS2-VASc risk factors slightly improved discrimination for stroke/SE: CHA2DS2-VASc risk factors alone C-index (Standard Error) was 0.6867 (0.0125) vs. CHA2DS2-VASc risk factors plus OSA 0.6876 (0.0124), p=0.022. Figure 1. Hazard ratios with 95% confidence intervals and event rates for the association between obstructive sleep apnea and major adverse cardiovascular and neurological events combined and separately. Abbreviations: OSA; obstructive sleep apnea MACNE; major adverse cardiovascular and neurological events, CV; cardiovascular, TIA; transient ischemic attack. Conclusion One in five patients with AF in community practice had OSA. The presence of OSA was associated with higher risk of MACNE and stroke/SE. Addition of OSA to CHA2DS2-VASc risk factors only slightly improved discrimination for the occurrence of stroke. Acknowledgement/Funding The Danish Heart Foundation, T32 NIH Grant HL079896. The ORBIT-AF registry is sponsored by Janssen.
Rate of Initial Hearing Loss During Early Observation Predicts Time to Non-Serviceable Hearing in Patients With Conservatively Managed Sporadic Vestibular Schwannoma
Carlson, Matthew L. , Dowling, Eric M. , Lohse, Christine M. , O’Connell, Brendan P., Driscoll, Colin L. W., Haynes, David S. , Link, Michael J. , Hunter, Jacob B. , Hunter, Jacob B

Mayo Clinic

Otology & Neurotology | October 20, 2019 | Volume: 40 | Issue: 10 | Pages: e1012-e1017

10.1097/mao.0000000000002390 | PMID 31634279 Get It

Objective: To date, prediction models for estimating risk of acquiring non-serviceable hearing in subjects with observed vestibular schwannoma (VS) have evaluated outcomes primarily based on features at initial diagnosis. Herein, we evaluate the association of rate of hearing decline during the initial period of observation with time to non-serviceable hearing. If significant, rate of hearing decline may inform decision making after an introductory period of observation. Setting: Two tertiary care centers. Patients: VS patients with serviceable hearing who underwent at least three audiograms and two magnetic resonance imaging (MRI) studies before intervention or being lost to follow-up. The rate of change in pure-tone average (PTA) and word recognition score (WRS) was calculated as the score from the second audiogram minus the score from the first audiogram, divided by the duration in months between the two. Main Outcome Measure(s): Serviceable hearing, defined as PTA ≤50 dB HL and WRS ≥50%. Results: Among 266 patients meeting inclusion criteria, 52 developed non-serviceable hearing at last follow-up. Kaplan–Meier estimated rates of maintaining serviceable hearing (95% CI; number still at risk) at 1, 3, 5, 7, and 10 years were 97% (95–100; 206), 78% (72–85; 98), 68% (60–77; 39), 60% (50–73; 17), and 44% (29–67; 2), respectively. In a univariable setting, each 1 dB increase per month in the rate of initial PTA change was associated with a 96% increased likelihood of acquiring non-serviceable hearing (hazard ratio [HR] 1.96; 95% CI 1.44–2.68; p < 0.001). Each 1% increase per month in the rate of initial WRS change was associated with a decreased likelihood of acquiring non-serviceable hearing (hazard ratio [HR] 0.79; 95% confidence interval [CI] 0.66–0.94; p = 0.009). After multivariable adjustment, both rate of PTA change (HR 2.42; 95% CI 1.72–3.41; p < 0.001) and rate of WRS change (HR 0.81; 95% CI 0.67–0.99; p = 0.043) remained statistically significantly associated with time to non-serviceable hearing. Conclusion: Rate of early PTA and WRS decline during the initial period of observation are significantly associated with time to development of non-serviceable hearing. This information may facilitate accurate patient counseling and inform decision-making regarding prospective disease management.
Radiological and clinical predictors of scoliosis in patients with Chiari malformation type I and spinal cord syrinx from the Park-Reeves Syringomyelia Research Consortium
Strahle, Jennifer M. , Taiwo, Rukayat , Averill, Christine, Torner, James C., Shannon, Chevis N. , Bonfield, Christopher M. , Tuite, Gerald F. , Bethel-Anderson, Tammy, Rutlin, Jerrel, Brockmeyer, Douglas L. , Wellons, John C. , Leonard, Jeffrey R. , Mangano, Francesco T. , Johnston, James M. , Iskandar, Bermans J. , Tyler‐Kabara, Elizabeth C. , Jackson, Eric M. , Couture, Daniel E., Adelson, P. David , Alden, Tord D. , Aldana, Philipp R. , Anderson, Richard C. E. , Baird, Lissa , Bierbrauer, Karin S. , Chern, Joshua J. , Whitehead, William E. , Ellenbogen, Richard G. , Fuchs, Herbert E., Guillaume, Daniel, Hankinson, Todd C. , Iantosca, Mark, Oakes, W. Jerry, Keating, Robert F., Khan, Nickalus R. , Muhlbauer, Michael S., McComb, J. Gordon , Menezes, Arnold H. , Ragheb, John , Smith, Jodi L. , Maher, Cormac O. , Greene, Stephanie , Kelly, Michael P. , O’Neill, Brent R., Krieger, Mark D., Tamber, Mandeep S. , Durham, Susan, Olavarria, Greg, Stone, Scellig , Kaufman, Bruce A., Heuer, Gregory G. , Bauer, David F. , Albert, Gregory W. , Greenfield, Jeffrey P. , Wait, Scott D. , Poppel, Mark D Van, Eskandari, Ramin , Mapstone, Timothy B., Dacey, Ralph G. , Park, Tae Sung, Limbrick, David D. , Torner, James C. , Kelly, Michael P , Shah, Manish N. , Daniels, David J. , Grant, Gerald A. , Selden, Nathan R. W. , Guillaume, Daniel J., Shimony, Joshua S. , Limbrick, David D.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | October 19, 2019 | Volume: 24 | Issue: 5 | Pages: 520-527

10.3171/2019.5.peds18527 | PMID 31419800 Get It

OBJECTIVEScoliosis is frequently a presenting sign of Chiari malformation type I (CM-I) with syrinx. The authors’ goal was to define scoliosis in this population and describe how radiological characteristics of CM-I and syrinx relate to the presence and severity of scoliosis.METHODSA large multicenter retrospective and prospective registry of pediatric patients with CM-I (tonsils ≥ 5 mm below the foramen magnum) and syrinx (≥ 3 mm in axial width) was reviewed for clinical and radiological characteristics of CM-I, syrinx, and scoliosis (coronal curve ≥ 10°).RESULTSBased on available imaging of patients with CM-I and syrinx, 260 of 825 patients (31%) had a clear diagnosis of scoliosis based on radiographs or coronal MRI. Forty-nine patients (5.9%) did not have scoliosis, and in 516 (63%) patients, a clear determination of the presence or absence of scoliosis could not be made. Comparison of patients with and those without a definite scoliosis diagnosis indicated that scoliosis was associated with wider syrinxes (8.7 vs 6.3 mm, OR 1.25, p < 0.001), longer syrinxes (10.3 vs 6.2 levels, OR 1.18, p < 0.001), syrinxes with their rostral extent located in the cervical spine (94% vs 80%, OR 3.91, p = 0.001), and holocord syrinxes (50% vs 16%, OR 5.61, p < 0.001). Multivariable regression analysis revealed syrinx length and the presence of holocord syrinx to be independent predictors of scoliosis in this patient cohort. Scoliosis was not associated with sex, age at CM-I diagnosis, tonsil position, pB–C2 distance (measured perpendicular distance from the ventral dura to a line drawn from the basion to the posterior-inferior aspect of C2), clivoaxial angle, or frontal-occipital horn ratio. Average curve magnitude was 29.9°, and 37.7% of patients had a left thoracic curve. Older age at CM-I or syrinx diagnosis (p < 0.0001) was associated with greater curve magnitude whereas there was no association between syrinx dimensions and curve magnitude.CONCLUSIONSSyrinx characteristics, but not tonsil position, were related to the presence of scoliosis in patients with CM-I, and there was an independent association of syrinx length and holocord syrinx with scoliosis. Further study is needed to evaluate the nature of the relationship between syrinx and scoliosis in patients with CM-I.
O4‐10‐04: LARGE‐SCALE PROTEOMIC ANALYSIS OF HUMAN PREFRONTAL CORTEX IDENTIFIES PROTEINS ASSOCIATED WITH COGNITIVE TRAJECTORY IN ADVANCED AGE
Breen, Michael S. , Troncoso, Juan C. , Thambisetty, Madhav , Beach, Thomas G. , Reiman, Eric M. , Caselli, Richard J. , Seyfried, Nicholas T. , Wingo, Aliza P. , Dammer, Eric B. , Logsdon, Ben , Duong, Duc M , Serrano, Geidy E. , Lah, James J. , Levey, Allan I. , Wingo, Thomas S

Mayo Clinic

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_24 | Pages: No page available

10.1016/j.jalz.2019.06.4797 Get It

O3‐02‐02: AMYLOID PET, TAU PET, AND MRI MEASUREMENTS IN COGNITIVELY UNIMPAIRED PERSONS WITH TWO, ONE, AND NO COPIES OF THE APOE4 ALLELE
Goradia, Dhruman D., Protas, Hillary , Bauer, Robert, Devadas, Vivek, Tariot, Pierre N. , Lowe, Val J. , Petersen, Ronald C. , Caselli, Richard J. , Su, Yi , Reiman, Eric M. , Ghisays, Valentina , Knopman, David S. , Jack, Clifford R. , Su, Yi, Chen, Kewei

Mayo Clinic

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_17 | Pages: No page available

10.1016/j.jalz.2019.06.4631 Get It

IC‐P‐189: REGIONAL AND VOXEL‐WISE SPATIAL RELATIONSHIPS AMONG FLUORINE‐18 AMYLOID PET TRACERS AND PITTSBURGH COMPOUND B
Adedokun, Adedamola, Marple, Laura M., Chen, Gengsheng , Hornbeck, Russ C. , Soucy, Jean‐Paul , Noto, Richard B., Jiménez‐Velázquez, Ivonne Z. , Gauthier, Serge , Surti, Ghulam M., Farlow, Martin R. , Salloway, Stephen , Flores, Shaney , Su, Yi , Gordon, Brian A. , Wang, Qing , Jack, Clifford R. , Roberson, Erik D. , Brooks, William S. , Hsiung, Ging‐Yuek Robin , McDade, Eric , Bateman, Randall J. , Benzinger, Tammie L.S.

Mayo Clinic

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_3 | Pages: No page available

10.1016/j.jalz.2019.06.4304 Get It

P3‐426: REGIONAL AND VOXEL‐WISE SPATIAL RELATIONSHIPS AMONG FLUORINE‐18 AMYLOID PET TRACERS AND PITTSBURGH COMPOUND B
Adedokun, Adedamola, Marple, Laura M., Chen, Gengsheng , Hornbeck, Russ C. , Soucy, Jean‐Paul , Noto, Richard B., Jiménez‐Velázquez, Ivonne Z. , Gauthier, Serge , Surti, Ghulam M., Farlow, Martin R. , Salloway, Stephen , Flores, Shaney , Su, Yi, Gordon, Brian A. , Wang, Qing , Jack, Clifford R. , Roberson, Erik D. , Brooks, William S. , Hsiung, Ging‐Yuek Robin , McDade, Eric , Bateman, Randall J. , Benzinger, Tammie L.S.

Mayo Clinic

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_21 | Pages: No page available

10.1016/j.jalz.2019.06.3460 Get It

P3‐387: SURFACE‐BASED HIPPOCAMPAL MORPHOMETRY ANALYSIS FOR STUDYING EFFECTS OF APOE‐E4 ALLELE LOAD IN COGNITIVELY UNIMPAIRED SUBJECTS
Wu, Jianfeng , Li, Bolun , Schron, Emily H., McMahon, Travis, Reiman, Eric M. , Caselli, Richard J., Dong, Qunxi , Zhang, Wen, Shi, Jie , Gutman, Boris A , Chen, Kewei , Baxter, Leslie C. , Thompson, Paul M. , Caselli, Richard J. , Wang, Yalin

Mayo Clinic

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_21 | Pages: No page available

10.1016/j.jalz.2019.06.3420 Get It

Oxybutynin vs Placebo for Hot Flashes in Women With or Without Breast Cancer: A Randomized, Double-Blind Clinical Trial (ACCRU SC-1603)
Leon‐Ferre, Roberto A. , Novotny, Paul J. , Wolfe, Eric, Ruddy, Kathryn J. , Flora, Daniel , Dakhil, Christopher, Rowland, Kendrith M. , Graham, Mark L., Le‐Lindqwister, Nguyet, Loprinzi, Charles L. , Wolfe, Eric G, Ruddy, Kathryn J , Smith, Thomas J , Faubion, Stephanie S. , Smith, Thomas J.

Mayo Clinic

JNCI Cancer Spectrum | October 18, 2019 | Volume: 4 | Issue: 1 | Pages: No page available

10.1093/jncics/pkz088 | PMID 32337497 Get It

Abstract Background Hot flashes (HFs) negatively affect quality of life among perimenopausal and postmenopausal women. This study investigated the efficacy of oxybutynin vs placebo in decreasing HFs. Methods In this randomized, multicenter, double-blind study, women with and without breast cancer with 28 or more HFs per week, lasting longer than 30 days, who were not candidates for estrogen-based therapy, were assigned to oral oxybutynin (2.5 mg twice a day or 5 mg twice a day) or placebo for 6 weeks. The primary endpoint was the intrapatient change from baseline in weekly HF score between each oxybutynin dose and placebo using a repeated-measures mixed model. Secondary endpoints included changes in weekly HF frequency, HF-related daily interference scale questionnaires, and self-reported symptoms. Results We enrolled 150 women. Baseline characteristics were well balanced. Mean (SD) age was 57 (8.2) years. Two-thirds (65%) were taking tamoxifen or an aromatase inhibitor. Patients on both oxybutynin doses reported greater reductions in the weekly HF score (5 mg twice a day: −16.9 [SD 15.6], 2.5 mg twice a day: −10.6 [SD 7.7]), placebo −5.7 (SD 10.2); P &lt; .005 for both oxybutynin doses vs placebo), HF frequency (5 mg twice a day: −7.5 [SD 6.6], 2.5 mg twice a day: −4.8 [SD 3.2], placebo: −2.6 [SD 4.3]; P &lt; .003 for both oxybutynin doses vs placebo), and improvement in most HF-related daily interference scale measures and in overall quality of life. Patients on both oxybutynin arms reported more side effects than patients on placebo, particularly dry mouth, difficulty urinating, and abdominal pain. Most side effects were grade 1 or 2. There were no differences in study discontinuation because of adverse effects. Conclusion Oxybutynin is an effective and relatively well-tolerated treatment option for women with HFs.